[1] ICH.Maintenance of the ICH guideline on clinical safety data management: data elements for transmission of individual case safety reports E2B (R2)[EB/OL].(2001-01-05)[2019- 09-07]. https://wenku.baidu.com/view/4cebcd0fba1aa 8114431d947.html. [2] 武楠,杨悦.欧盟药物警戒数据库建设对我国的启示[J]. 中国药物警戒, 2018, 15(4): 230-233. [3] Hennig Renald.Electronic Reporting for Clinical Drug Safety and Pharmacovigilance[J].Expert Opinion on Drug Safety, 2003,2(2):195-197. [4] 叶小飞,郭晓晶,赵璐,等.个例安全性报告规范(ICH E2B)简介及应用[J].中国药物警戒,2012,9(3):149-151. [5] ICH.ICH M2工作组介绍[EB/OL].(2019-08)[2019-09-07]. http://estri.ich.org/index.html. [6] 荆宁宁,程俊瑜.数据、信息、知识与智慧[J].情报科学, 2005,23(12):1786-1790. [7] Ralph Edwards,Marie Lindquist Editors.Pharmacovigilance Critique and Ways Forward[M].Springer International Publishing Switzerland,2017:XV-XVi. [8] Lindquist D M.Data Quality Management in Pharmacovigilance[J]. Drug Safety,2004,27(12):857. [9] Nelson J C,Cook A J,Yu O,et al.Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data[J].Pharmacoepidemiology & Drug Safety, 2012, 21(S1):62-71. [10] Kelly W K,Halabi S.Reporing of Adverse Event[M].America: Springer Publishing Company,2018,141-149. [11] DIA.从生产企业角度如何改善临床试验中的安全性报 告[EB/OL]. (2018-06-07)[2019-09-07].https://mp.weixin.qq.com/s/86XN2FCB28S2OwUlyQi5Pg. [12] EU.EudraVigilance-European database of suspected adverse drug reaction report-Background[EB/OL].[2019-09-07]. http://www.adrreports.eu/en/background.html. [13] 蔡婷,闫磊,刘述森,等.我国药品上市后重点监测相关 问题的探讨[J].药物流行病学杂志, 2017,26(5): 5-9,32. [14] ICH.Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) E2B(R3) Data Elements and Message Specification[EB/OL].(2016-11-10) [2019-09-07]. https://www.ich.org/products/guidelines/ efficacy/article/efficacy-guidelines.html. [15] NMPA.总局关于适用国际人用药品注册技术协调会二级 指导原则的公告(2018年第10号)[EB/OL].(2018-01-25) [2019-09-07]. http://www.nmpa.gov.cn/WS04/CL2138/ 300493.html. |